E1	And:T1 Arg:T46 Arg2:E2
E2	Condition:T2 Name:T47
E3	And:T3 Arg:E2 Arg2:E4
E4	Assertion:T4 
E5	Or:T5 Arg:E4 Arg2:E6
E6	Procedure:T6 Name:T77
E7	Eq-Comparison:T7 Temporal-Period:T78
E8	Procedure:T8 Name:T48 Temporality:E7
E9	Age:T9 Eq-Comparison:E10
E10	Eq-Comparison:T10 Operator:T49 Value:T50 Temporal-Unit:T51
E11	Observation:T11 Name:T53 Polarity:T52
E12	Condition:T12 Name:T54
E13	Condition:T13 Name:T55
E14	Or:T14 Arg:E13 Arg2:E16
E15	Eq-Comparison:T15 Temporal-Period:T56
E16	Condition:T16 Name:T57 Temporality:E15
E17	Condition:T17 Name:T58
E20	Condition:T20 Name:T61
E21	Condition:T21 Name:T62
E22	Negation:T22 
E23	Eq-Comparison:T23 Temporal-Period:T63
E24	Assertion:T24 
E25	Or:T25 Arg:E24 Arg2:E26
E26	Procedure:T26 Name:T80 Temporality:E23
E27	Procedure:T27 Name:T64
E28	Procedure:T28 Name:T65
E29	Temporal-Connection:T29 Arg:E28 Arg2:E30
E30	Study:T30 
E31	Other:T31 Is-Other:E33
E32	Modifier:T32 Modifies:T66
E33	Drug:T33 Name:T66
E34	Other:T34 Is-Other:E35
E35	Drug:T35 Name:T67
E37	Drug:T37 Name:T68
E45	And:T79 Arg:E11 Arg2:E12
E18	Modifier:T18 Modifies:T58
E19	Procedure:T19 Name:T60
E46	Temporal-Connection:T59 Arg:E19 Arg2:E20
E47	And:T81 Arg:E26 Arg2:E27
E48	Negation:T82 Negates:E28
E36	Drug:T36 Name:T38
E38	Drug:T39 Name:T40
E39	Drug:T41 Name:T42
E40	Drug:T43 Name:T44
E41	Drug:T69 Name:T70
E42	Drug:T71 Name:T72
E43	Drug:T73 Name:T74
T1	And 162 166	with
T2	Condition 167 196	immune mediated enteropathies
T3	And 197 200	who
T4	Assertion 210 233	improvement in symptoms
T5	Or 234 237	and
T6	Procedure 238 247	histology
T7	Eq-Comparison 248 250	on
T8	Procedure 251 274	oral budesonide therapy
T9	Age 300 303	Age
T10	Eq-Comparison 304 313	<18 years
T11	Observation 328 348	stool gluten testing
T12	Condition 366 391	refractory celiac disease
T13	Condition 397 419	Small bowel malignancy
T14	Or 420 422	or
T15	Eq-Comparison 423 430	history
T16	Condition 434 456	small bowel malignancy
T17	Condition 462 487	Refractory celiac disease
T20	Condition 516 544	lymphoproliferative disorder
T21	Condition 556 567	enteropathy
T22	Negation 573 575	No
T23	Eq-Comparison 576 581	prior
T24	Assertion 582 605	improvement in symptoms
T25	Or 606 609	and
T26	Procedure 610 619	histology
T27	Procedure 625 643	budesonide therapy
T28	Procedure 668 686	budesonide therapy
T29	Temporal-Connection 687 695	prior to
T30	Study 700 705	trial
T31	Other 711 716	Other
T32	Modifier 717 736	concurrent systemic
T33	Drug 737 752	corticosteroids
T34	Other 758 763	Other
T35	Drug 764 792	immune mediating medications
T37	Drug 825 837	azathioprine
T45	Location 112 140	Mayo Clinic in Rochester, MN
T46	Life-Stage-And-Gender 147 152	Adult
T47	Condition-Name 167 196	immune mediated enteropathies
T48	Procedure-Name 251 274	oral budesonide therapy
T49	Eq-Operator 304 305	<
T50	Eq-Value 305 307	18
T51	Eq-Temporal-Unit 308 313	years
T52	Polarity 319 327	Positive
T53	Observation-Name 328 348	stool gluten testing
T54	Condition-Name 366 391	refractory celiac disease
T55	Condition-Name 397 419	Small bowel malignancy
T56	Eq-Temporal-Period 423 430	history
T57	Condition-Name 434 456	small bowel malignancy
T58	Condition-Name 462 487	Refractory celiac disease
T60	Procedure-Name 505 515	transplant
T61	Condition-Name 516 544	lymphoproliferative disorder
T62	Condition-Name 556 567	enteropathy
T63	Eq-Temporal-Period 576 581	prior
T64	Procedure-Name 625 643	budesonide therapy
T65	Procedure-Name 668 686	budesonide therapy
T66	Drug-Name 737 752	corticosteroids
T67	Drug-Name 764 792	immune mediating medications
T68	Drug-Name 825 837	azathioprine
T76	Location 60 103	Division of Gastroenterology and Hepatology
T77	Procedure-Name 238 247	histology
T78	Eq-Temporal-Period 248 250	on
T79	And 361 365	with
T18	Modifier 488 494	type 2
T19	Procedure 505 515	transplant
T59	Temporal-Connection 500 504	Post
T80	Procedure-Name 610 619	histology
T81	And 620 624	with
T82	Negation 649 664	Discontinuation
T36	Drug 839 855	6-mercaptopurine
T38	Drug-Name 839 855	6-mercaptopurine
T39	Drug 857 869	cyclosporine
T40	Drug-Name 857 869	cyclosporine
T41	Drug 871 883	methotrexate
T42	Drug-Name 871 883	methotrexate
T43	Drug 885 915	anti-TNF monoclonal antibodies
T44	Drug-Name 885 915	anti-TNF monoclonal antibodies
T69	Drug 917 971	alpha-4 beta-7 integrin inhibiting monoclonal antibody
T70	Drug-Name 917 971	alpha-4 beta-7 integrin inhibiting monoclonal antibody
T71	Drug 973 1021	interleukin 12/23 inhibiting monoclonal antibody
T72	Drug-Name 973 1021	interleukin 12/23 inhibiting monoclonal antibody
T73	Drug 1023 1037	JAK inhibitors
T74	Drug-Name 1023 1037	JAK inhibitors
A1	Assertion-Type-Value E4 hypothetical
A2	Assertion-Type-Value E24 hypothetical
A3	Temporal-Connection-Type-Value E29 before
A4	Location-Value T45 hospital
A5	Life-Stage-And-Gender-Type T46 adult
A6	Eq-Operator-Value T49 LT
A7	Eq-Temporal-Unit-Value T51 year
A8	Polarity-Value T52 positive
A9	Observation-Type-Value T53 lab
A10	Eq-Temporal-Period-Value T56 past
A11	Eq-Temporal-Period-Value T63 past
A12	Location-Value T76 clinic
A13	Eq-Temporal-Period-Value T78 present
A14	Temporal-Connection-Type-Value E46 after
R1	Caused-By Arg1:E21 Arg2:E20
R2	Abbrev-Of Arg1:E22 Arg2:E26
R3	Example-Of Arg1:E37 Arg2:E35
R4	Example-Of Arg1:E36 Arg2:E35
R5	Example-Of Arg1:E38 Arg2:E35
R6	Example-Of Arg1:E39 Arg2:E35
R7	Example-Of Arg1:E40 Arg2:E35
R8	Example-Of Arg1:E41 Arg2:E35
R9	Example-Of Arg1:E42 Arg2:E35
R10	Example-Of Arg1:E43 Arg2:E35
